Cadmium exposure during pregnancy and lactation: materno-fetal and newborn repercussions of Cd(II), and Cd–metallothionein complexes by Espart Herrero, Anna et al.
This journal is©The Royal Society of Chemistry 2018 Metallomics, 2018, 10, 1359--1367 | 1359
Cite this:Metallomics, 2018,
10, 1359
Cadmium exposure during pregnancy and
lactation: materno-fetal and newborn
repercussions of Cd(II), and Cd–metallothionein
complexes
Anna Espart, *ab Sebastia´n Artime,c Glo`ria Tort-Nasarre a and
Edinson Yara-Varo´n d
Cadmium (Cd) is a non-physiological heavy metal that can be harmful at low concentrations. Increasing
anthropogenic activities are incrementing the risk of accumulation of this heavy metal in different
organs and tissues of the body. In the case of pregnant women, the threat is more serious due to the
implications affecting not only their own health but also fetal development as well. Metallothioneins
(MTs), small cysteine-rich proteins, are involved in zinc (Zn) and copper homeostasis in mammals but
can, however, also bind with Cd if present. The accumulation of Cd in maternal tissues (e.g. placenta,
maternal blood, and mammary glands) induces the synthesis of MTs, preferably MT2, in an attempt to
sequester the metal to avoid toxicity. The formed Cd–MT complexes will avoid the Cd transport from
the placenta to the fetus and end up accumulating in the maternal kidneys. At the same time, high
concentrations of MTs will increase the formation of Zn–MT complexes, therefore decreasing the
amount of Zn ions available to be transported to the fetus by means of Zn transporters such as ZnT2,
ZIP14 and DMT1. Although MTs cannot transport Cd from the mother to the fetus, the divalent DMT1
transporter is suggested to carry the metal to the fetus. As a consequence, the low levels of Zn(II) in the
fetus, together with the presence of Cd(II) coming from the mother either via the placenta and cord
blood or via breast milk induce changes in the fetal development including fetal growth retardation, and
low weight or height of the newborn. Likewise, the concentrations of Cd(II) in the newborn can cause
alterations such as cognitive disabilities. In summary, the presence of Cd(II) in the maternal tissues will
induce MT synthesis in an attempt to detoxify these tissues and reduce the possible toxicity of Cd in
fetal and newborn tissues.
Significance to metallomics
Environmental health has been a growing concern in recent years. Understanding the molecular mechanisms involved in the alterations caused by pollutants is
essential in order to act accordingly. Cadmium (Cd) is a toxic metal, whose presence may threaten the health of the mother and the fetus. The main points
(topics) to be addressed are the following: where Cd(II) is mainly accumulated, where and why metallothionein (MT) synthesis is induced, how Cd is bound to
MTs and what happens with Zn and Cd transport from the mother to the fetus. Knowledge of the main implications caused by the presence of Cd will allow us
to establish future strategies at a different level.
1. Introduction
1.1. Cadmium exposure overview
Cadmium (Cd) is a heavy metal that is naturally present at low
levels in the environment. Besides the natural sources of Cd
production (i.e. mainly volcanic activity, erosion and river
transport), anthropogenic activities have turned Cd into a
serious pollutant in different settings, in recent decades. The
most common sources of Cd pollution caused by humans are
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agricultural (manufacture of phosphate fertilizers), industrial
(such as mining, smelting and refining of different metals,
coating and plating and pigment manufacture) and urban-life
related (including waste and recycling products containing Cd:
batteries, electronic devices and plastic components).1–3
It is known that Cd is toxic to living beings as well as
carcinogenic, according to the International Agency for Research
on Cancer (IARC);4 however, only the ionized form – Cd(II) – is
able to cause cellular damage. Unlike other heavy metals with
similar chemical properties, in terms of protein binding, such as
zinc (Zn) or copper (Cu),5 Cd does not participate in physiological
functions in the human body, which means that Cd at any
concentration can be harmful.6 In fact, the chemical similarities
that Cd shares with different elements – Zn, iron (Fe) or calcium –
mean that Cd can replace them in the prosthetic group of several
proteins, altering not only the structure, but also some functions
such as enzymatic reactions by means of the depletion of the
thiol groups of antioxidants and enzymes.7,8 So, the main toxic
effects induced by Cd include oxidative stress, apoptosis in
embryonic cells or epigenetic changes, mainly by DNAmethylation
modifications.9–11
In humans, the main route of Cd exposure is by air, which is
responsible for up to 50% of the total Cd incorporation into the
organism. Specifically, tobacco is one of the major sources of
Cd in active and passive smokers. Nevertheless, Cd can also enter, to
a lesser extent, through contaminated food and drinking-water.1,2,12
As a direct consequence, the presence of Cd in the organism is
associated with alterations in the respiratory tract, the gastro-
intestinal tract, and the cardiovascular, renal and nervous
systems and it even affects bone health, being associated with
osteoporosis and osteomalacia.13
To deal with the harmful effects that the presence of Cd can
cause, organisms use specific mechanisms that besides their
specific function can help to avoid the toxicity of Cd. Among
them, metallothioneins (MTs) play a relevant role.
1.2. Basics of mammalian metallothioneins
MTs are a superfamily of ubiquitous, small to medium-sized
(o30 kDa)14,15 cysteine-rich (15–30%) proteins with the ability
to coordinate metal ions through metal–thiolate bonds and
have been identified in all eukaryotes and some prokaryotes
thus far analysed.16–18 The variety in the metal ion coordination
that MTs show, reveal particularities in the three-dimensional
metal–MT complexes. So, when the vertebrate MTs coordinate
divalent metal ions (Zn(II) or Cd(II)), two domains (b and a) can
be distinguished.19,20
The MT system comprises four extremely similar isoforms
(MT1 to MT4) which are specific to mammals even if in humans
MTs can differ into several subisoforms, as a result of amplifications
through evolution.21 As many as nine subisoforms of MT1 have
been described, while only one isoform of MT2, one of MT3 and
one of MT4 have been characterized thus far. MT1 and MT2 are
found in virtually all tissues. These are responsible for metal ion
homeostasis and transport, as well as protection against metal
toxicity and oxidative stress, either by protein overexpression
and sequestration of toxic metals, or by the direct involvement
of the free radical binding activity of MTs, and avoiding DNA,
RNA and cell structure damage.22 Their expression is signifi-
cantly high in the kidneys and the liver. Nevertheless, unlike the
MT1 gene, MT2 exhibits a basal expression globally, except in
the spleen where MT2 is not detectable.MT3 is mostly expressed
in the brain, where it plays specific roles in the central nervous
system, and finally,MT4 is expressed exclusively in the stratified
squamous epithelia.23–28 All four MTs are synthesized in the
maternal decidua in mice.29
Regarding the MT gene expression, they are commonly
expressed at a basal level; nevertheless, the expression of the
MT1/2 genes can increase in the presence of metal and non-
metal agents, which interact with the transcription factors
inducing MT synthesis.30,31 The induction of the mammalian
MT1/2 genes is sensitive to several metals – including Cd and
Zn – reactive oxygen species, glucocorticoids or cytokines. It is worth
noting that to induceMTs at the same level, the concentration of Zn
needs to be higher than the Cd concentration.32 Likewise, it has
long been known that the MT2 gene preferably responds to Zn(II)
and glucocorticoids, while MT1 does the same in the presence of
Cd(II) and to a lesser extent, to hormonal agents. With regards to the
MT3 gene, its induction is not influenced by these factors.33,34
At the same time, specific biological and environmental
conditions in human life, such as pregnancy and lactation,
ageing, smoking or pollution, may indirectly regulate the MT
concentrations in the tissues and organs, to deal with specific
changes that may occur in such conditions.9,35,36
1.3. Cd exposure during pregnancy and lactation
Cd reaches pregnant and nursing mothers mainly by smoking,
intake of Cd-contaminated food or water and even as a consequence
of the polluted environment.1–3 The physiological changes that
occur during pregnancy, such as an increased respiratory rate
or alterations in the gastrointestinal system in order to meet the
nutritional needs during embryo/fetus development, facilitate
the absorption of Cd.37,38 At the molecular level, its toxicity can
reduce Zn transport from the mother to the fetus/newborn,
induce MT gene expression in specific tissues32 or displace the
Zn in the Zn–MT complexes to form Cd–MT complexes.39,40
These modifications alone or in combination threaten both
good materno-fetal and newborn health.
As a result, specific tissues and fluids involved in pregnancy
and lactation processes (e.g. placenta, cord blood, embryonic/
fetal tissues, and mammary glands), can accumulate Cd as free
or bound metal ions. Its presence has been negatively associated
with alterations in the mother, the fetus and the newborn’s
health.41,42 Thus, studies conducted in rats have shown a significant
association between the presence of Cd and problems getting
pregnant, preeclampsia, kidney damage, alteration in essential
element levels or lower bone mineral density, among other adverse
effects.41 Likewise, there has been a direct correlation described
between the presence of Cd in the urine of pregnant women and a
reduction of the birth weight, height and cranial circumference of
the newborn. Similarly, the exposure to Cd in the middle and late
pregnancy increases the concentration of this metal in the blood
of the pregnant women and is linked to fetal growth retardation
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(FGR)42–45 due to the functional and/or structural abnormalities
induced by this metal.46 In addition, the toxic effects of Cd have
been also detected at the molecular level, where characteristic
DNA methylations have been identified.47,48
Regarding the lactation period, studies conducted in suckling
rats fed with breast milk containing Cd, revealed brain alterations.
These included changes in reflexes and physical maturation, delay
in neuromotor development and hyperactivity.49
The aim of this work is to review what is known so far about
the relationship between the Cd exposure of pregnant and
nursing mothers in mammals, the presence of Cd(II) in specific
tissues, organs or fluids, and the synthesis of MTs and their
repercussions.
2. Metal selectivity of MTs
MTs can be classified depending on their origin and structure.
However, this classification does not easily reflect the possible
functions in which MTs are involved. According to Palacios et al.,
the identification of the metal-binding features contributes to
characterizing the physiological functions of these metallo-
proteins. So, in vitro metal-replacement studies of MTs treated
with Zn(II), Cd(II) or Cu(I) have allowed identification of genuine
Zn–, Cd– or Cu–thioneins (i.e. formation of homometallic
species) as well as MTs that bind a mixture of two metals (i.e.
formation of heterometallic species). Thus, depending on the
behaviour of the MTs forming well-structured species with a
single metal, or low-structured species containing a mixture of
metals (Zn(II)/Cd(II) or Cu(I)/Cd(II)), a gradation can be established
according to the preference of the MTs for the metals. Likewise,
the coordination environment induces the protein to establish a
particular metal–MT folding which will result in a specific
structure and function of this particular complex.5
Focusing on these features of mammalian MTs, MT1/MT2
are considered typical Zn–thioneins, whereas MT4 presents a
strong Cu–thionein feature, and shows a weak ability to bind Zn
or Cd.5,50 The analysis of the binding abilities of the mammalian
MT1 and MT2 also revealed that they differ significantly from
each other. Despite the fact they share a very close degree of
coincidence in their metal binding behaviour. According to Artells
et al., MT1 exhibits a typical metal binding Cd(II) detoxifying
behaviour, whereas MT2 displays a closer Zn–thionein behaviour
for Zn(II) handling and homeostasis.39 However, according to
Vallee and Palmiter, it possibly cannot be considered that the
Cd detoxification is a function gained through evolution, but a
mere property that these proteins can take advantage of, when
Cd is present.51,52
In particular, recombinant synthesis of MT1 and MT2, in
the presence of Zn(II) or Cd(II), yields Zn7– and Cd7–MT1/2,
respectively. More precisely, in vitro titration analysis of Zn7–
MT1/2 with Cd(II) shows Zn/Cd replacement as a progressive,
non-cooperative, incorporation of Cd(II) into the MT1 and MT2
complexes, passing from a homonuclear state of Zn7–MT to a
heteronuclear state of ZnxCdy–MT and lastly obtaining a new
homonuclear state with Cd7–MT complexes. Focusing on the b
and a domains and due to the number of cysteines as well as
their distribution in each domain, the a domain binds up to
four Cd ions, whereas the b domain only has three in stable
complexes.39,53 According to this, it is feasible to think of a
situation in which the presence of Cd(II) will progressively replace
Zn–MT complexes in the tissues where Cd(II) is accumulated until
practically all the free ions will be bound to the MT complexes.
However, there is much consensus following the idea that this
will occur only in vitro with a fully enriched Cd medium, but not
in vivo, where it seems that MTs form mostly partially metallated
species under basal conditions. It may be expected that when the
concentration of Cd exceeds the capacity of the free thiols to
collect the metal, then Zn displacement will occur.
That said, if Cd(II) can escape from being bound, not only
will it act as a toxic element on its own, but may also be
mobilized to other tissues where the same situation would be
repeated.
3. Materno-fetal transport of Zn and
Cd
3.1. General considerations of Zn in mammals
Zn is an essential heavy metal in living beings taking part in
different cellular processes. The main functions in which Zn is
involved in proteins are: structural, regulatory and catalytic,
among others.54 In addition, Zn in mammals is necessary for
the successful functioning of the immune and nervous system
and endocrine function.55 Under biological conditions, Zn does
not undergo redox changes and as a consequence, it cannot be
involved in electron transfer reactions, which is why the cellular
toxicity of Zn is lower – but not negligible – than that of other
physiological metals like Cu or Fe. Nonetheless, Zn can be toxic
to many cell types, which is why the regulation of the bound
ions is required to maintain appropriate cell conditions.56 To
ensure a correct amount of this metal with the proteins that
require it, the cells have developed a complex homeostatic
system to mobilize, exchange or bind Zn ions. The system
comprises Zn-transporters, low affinity ligands, metallochaper-
ones and chelators such as MTs; the latter are considered some
of the most significant Zn-binding proteins, which participate
in intracellular homeostasis by binding Zn ions.57,58 Hence, the
responsibility of the input and the output of Zn ions from cells
involves different Zn transporters, including those from the
ZIP, ZnT families or the divalent transporter DMT1.59,60
3.2. Zn deficiency during pregnancy and lactation
Zn is an indispensable metal during embryo/fetal development
and in the first years of the newborn’s life. Under normal
conditions (i.e. in the absence of Cd or other situations that
may affect the Zn homeostasis), the metal is transferred from
the mother to the embryo/fetus through the placenta or to the
newborn through breast milk.61 When the required Zn levels
are not met due to gestational Zn deficiency, complications
may occur in the embryo/fetus. These complications can range
from alterations in Zn homeostasis, epigenetic changes in the
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fetal MTs to FGR, newborn delivery complications, low weight,
low height or low cranial perimeter of the newborn.62,63 Like-
wise, early years of the postnatal stage are characterized by a
period of a rapid growth and development, requiring high
amounts of Zn. When the newborn is exclusively fed by
breastfeeding, the provision of adequate Zn levels in the breast
milk is essential in order to meet the newborn’s needs. If these
needs cannot be met, complications may arise, ranging from
growth delay to cognitive impairments in humans.49
It has been demonstrated that Cd exposure affects the
essential elements metabolism in which Zn homeostasis is
included. Cd exposure reduces the bioavailability of Zn by
means of changes in the normal expression of Zn transporters,
altering the transfer of this metal from the maternal blood to
the embryo/fetus or from the breast milk to the newborn.49,64
As a consequence, the required levels of Zn, in the embryo/fetus
or newborn, may be insufficient to maintain suitable physiological
functions, affecting their optimal health, as stated above.
3.3. Zn and Cd transport in pregnancy and lactation related
tissues
3.3.1. Placenta. Zn arrives in the placental syncytiotro-
phoblast, from the maternal blood as a result of ZIP proteins
and then it is delivered to the cord blood, reaching the fetus,
mainly by means of the ZnT2, ZIP14 and DMT1. Likewise, the
transport of Zn to the fetus through the placenta can be
influenced by different factors, among them: gestational age,
Zn levels in the maternal blood or changes in Zn transporter
synthesis.65 So, for example, in the case of low dietary Zn
intake, the expression of the ZnT in this tissue may decrease,
reducing the Zn transport to the fetus, in an attempt to avoid an
imbalance in the maternal Zn homeostasis.66,67
Furthermore, the placenta is regarded as the principal tissue
that acts as a natural barrier to avoid the transfer of harmful
substances from the pregnant woman to the embryo or fetus.
However, it is considered as a partial barrier, due to the ability
of some molecules to cross it.68 Cd is one of them, as it is able
to pass from the mother to the fetus, in addition to being
accumulated in the placental tissue.42,43,69 Placental Cd con-
centrations in pregnant women are usually high despite some
researchers detecting lower levels than others. This is probably
due to specific conditions and measurement techniques.70,71
The pathway that allows Cd to cross the placenta and enter the
fetus remains unclear, nevertheless studies performed in rats
by Nakamura et al. suggest that DMT1 is the protein involved in
the transport of Cd from the placenta to the fetus. On the other
hand, it seems that the presence of placental MTs would
contribute to avoiding Cd transfer, although for the time being,
the mechanism remains not well understood. According to
Nakamura et al., different levels of Cd in the placenta regulate
the induction of the metal transporters and also the expression
ofMT genes, indicating that the wholemechanism ofmobilisation
and transport of Cd in the placenta depends on different metal-
proteins including the MTs.59,72 Then, Wang et al. demonstrated
also in rats, that in the presence of Cd the Zn transporters, ZnT1
and ZnT2 are down-regulated, thus decreasing the probability of
Cd being transported to the fetus64 (Table 1). As a consequence, Zn
transfer from the placenta to the fetus will also be modified,
accumulating Zn in the placental tissues and decreasing its levels
in the fetus.73,74 Therefore, the presence of Zn and Cd in the fetus
is determined by a set of players, in which the concentration of
maternal Zn and Cd seems to play the main role.
3.3.2. Maternal and cord blood. Concentrations of Zn in
the maternal blood seem to be different depending on the
gestational trimester due to the requirements in the Zn homeostasis
during fetal development.75,76 However, despite the variability
existing in pregnant women, it is difficult to speak of an adequate
amount of Zn in the maternal blood. In fact, there are several
studies in the literature showing different concentrations of
plasma Zn in pregnant women according to diverse variables:
age, parity, pregnancy pathologies or even place of origin.77–80
Zn is transported from enterocytes into the maternal blood
thanks to ZnT1 and from there it reaches and enters the
placenta by means of ZIP proteins, as stated above.66 Once Zn
is in the placenta, it can be bound to MTs or transported to the
cord blood through Zn transporters which include ZIP14, ZnT2
and DMT1.59,72,81
In the case of Cd exposure, the presence of this toxic metal
in the maternal plasma is negatively related with the Zn and
Cu levels in the placenta due to down-regulation of Zn and
Table 1 Summary table of the repercussions of cadmium exposure, in different tissues and fluids and over metallothioneins, during pregnancy and
lactation. Cd: cadmium; Zn: zinc; Cu: copper; MTs: metallothioneins
Cd(II) MTs
Pregnancy Placenta and
uterus
 Transport to cord blood by means of DMT1.59,72  Cd–MT complex formation.29,63,93–96,101,102
 Down-regulation of Zn transporters.64  Induction of MT1 and upregulation of MT2.32
 Reduced transport of maternal Zn to fetus.73,74  Significant expression of MT3 in uterus.72
Maternal blood  Down-regulation of Zn and Cu transporters64,72  Higher concentrations of Cd in the case of
MT2-5A/G heterozygosis vs. homozygosis.103,104
Cord blood  Lower concentrations than in maternal blood.44,46,59,82  (Not enough significant data found)
Fetus  Accumulation in the kidneys and liver.41,59  Role of MT1 and MT2 unclear but it is suspected
to be similar to those in adults.104,107,108
Lactation Mammary gland  Down-regulation of Zn exporters (ZnT2, ZnT4)
and overexpression of Zn importers (ZIP3, ZIP4 and ZIP8).85
 Cd–MT complex formation.44
Breast milk  Presence of Cd(II) not totally retained by mammary
glands.66,72,83
 Lower amounts of MTs than in Cd absence.111
 Cd(II) bound to intestinal MT.59
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Cu transporters, which therefore proves that the toxic metal
modifies the concentration of the physiological ones.64,72 Similarly,
studies analysing the presence of Cd in thematernal and cord blood
of exposed pregnant women, find the concentrations of this metal
to be at least one and a half times higher in the maternal blood
rather than the cord blood,46 corroborating the low rate of Cd
transfer from themother to the fetus via the placenta, most likely as
a result of the MT role, avoiding its transport.44,59,82 However, Cd
reaches the cord blood and subsequently, the fetus.
3.3.3. Fetus. Zn reaches the fetus via the cord blood. If the
concentration of Zn in the placenta is not adequate or there is
no bioavailability of the metal because it is bound to other
molecules, its transfer through the cord blood can be altered.
This will result in alterations of fetal homeostasis of Zn, FGR or
changes in anthropometric parameters of the newborn with
lower than expected values, among other changes.60,79
When Cd is present in the placenta, it reaches the fetus,
although at low concentrations.72 Studies conducted by Nakamura
et al., revealed that rats on the first day of life, present higher
concentrations of Cd in their kidneys and liver, indicating that in
the fetal life, Cd has been present at least in the last intrauterine
period. Evenly, the Cd levels in these organs will depend on its
concentration in the mother.59 Likewise, the presence of Cd during
fetal development is related with a long list of alterations which
include modifications in the central nervous system, kidney or liver
development, imbalance in the homeostasis of essential elements
or FGR83 (for more detailed information, please refer to ref. 41).
3.3.4. Lactation (mammary glands and breast milk) and
the newborn. In the same way as the placenta, the mammary
glands act as a barrier between the maternal blood and the
breast milk. In fact, it seems that the mammary glands can
activate or inhibit the transport of essential elements. Since
breast milk has to meet all nutritional needs of the newborn,
there is an intense transport of essential elements, and Zn is
among them.84
According to Rossipal et al., the concentration of Zn in the
human colostrum can be higher than in the maternal blood.
However, despite the modulation of essential elements carried
out by this gland, it seems that the Cd transport is not completely
inhibited and Cd has been found in breast milk.66,72,83 At the
same time, the presence of Cd in the mammary glands causes a
down-regulation of ZnT2 and ZnT4 and an overexpression of
ZIP3, ZIP4 and ZIP8, which indicates that the Zn-transporters
play a significant role in the Zn transport and Cd retention in the
mammary glands85 (Table 1).
In turn, the formation of specific Cd–MT complexes in this
tissue has also been described,86 these formations would reduce the
transfer of this toxicmetal from the breastmilk to the newborn, and
thus diminish possible damage. So, one might affirm that the
changes in the expression of ZnT and ZIP transporter families,
together with the up-regulation of MTs in the mammary glands
respond to a dual need: on one hand, binding essential metals that
need to be mobilized from milk to the breastfed infant in order to
meet the higher requirements during breastfeeding;87 and on the
other hand, minimising the transport of toxic metals, such as Cd,
from milk to the newborn through its retention in the tissue.44
Furthermore, recent studies also demonstrated that low
concentrations of Cd contained in the breast milk and trans-
ferred to the newborn are able to reach their digestive system
where it will bind to the intestinal MTs.59 Similarly, studies
performed on lactating rats show that in early postnatal days,
the presence of Cd in the breast milk also induces the down-
regulation of ZnT and the overexpression of ZIP protein
families in the intestines of the newborn, as occurred in the
mammary gland,44 corroborating the same role that these
proteins play in the mother exposed to Cd.
4. Role of MTs in materno-fetal
transport of Zn and Cd
Even though this mini-review aims to explore the role of Cd(II)
and MTs in materno-fetal tissues in Cd exposure, it is worth
noting that other organs also experience changes as a con-
sequence of the presence of Cd, this being the case for the liver
and kidneys. So, specifically in the case of MTs at this stage, Cd
accumulates from the highest to the lowest concentrations in
the liver, serum, kidneys and placenta. In particular, the
maternal liver Cd inducesMT1 andMT2mRNA, which suggests
a crucial role of MT1 and MT2 binding Cd in this organ and
thus avoiding its presence in the placenta.64 Similarly, it has
been described that Cd in the liver may be mobilized as a
Cd–MT complex to other organs like the kidneys.88
When the MT concentrations increase in the maternal serum
during pregnancy, the Cd–MT complexes formed accumulate in
the kidneys.88 Since the complexes are more nephrotoxic than
Cd alone, the complications caused by the presence of Cd–MT
complexes in these organs may become irreversible89 (Table 1).
The role of MTs in the materno-fetal organs and tissues
related to Zn and Cd transport are detailed below.
4.1. Placenta and uterus
In human placental structures, MTs have been identified in the
decidua, the syncytiotrophoblasts and the amniotic cells, suggesting
that MTs play an important role in the metal (i.e. Zn, Cu, and Cd)
transport from mother to fetus.90 Therefore, it is well known that
MT1 and MT2 bind Zn(II) and the Zn–MT complexes formed
participate in the transport of Zn from mother to fetus.91
In Cd exposure, it has been demonstrated that MT concentra-
tions in the trophoblast cells are higher than in other placental
regions, which indicates that Cd accumulation in the trophoblastic
structures carries an increased risk for fetal development, and Cd
needs to be bound to avoid cell apoptosis.9,92 In fact, it has long
been known that the presence of Cd(II) induces the expression of
MT1 andMT2 genes in the uterine and placental tissues in a dose-
dependent relation.32 Likewise, it has been described that nearly all
free Cd ions are sequestered by proteins in the placenta, therefore
MT1 and MT2 are responsible for binding the metal. So, the
presence of Cd displaces the Zn during the metal–MT complex
formation, due to the higher affinity of MTs for Cd than for Zn,
thus reducing the toxicity of Cd(II) in the placenta.23,69,93–96
However, for the time being, the mechanism by which MT1
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and MT2 avoid Cd transfer but deliver essential metals such as
Zn to the embryo and fetus59 remains unclear.
The protective role that MT1 and MT2 play against the Cd
toxicity has been established. Moreover, the ratio of MT1/MT2
in the placenta changes due to the presence of Cd, MT2 being
up-regulated against MT1. This makes the concentrations of
MT1 and MT2 more similar, which could suggest that either the
up-regulation of MT2 happens to ensure adequate Zn handling
in the presence of Cd–MT1 complexes, or alternatively, it would
presuppose a more important role of MT2 in the detoxification
of Cd.64,72,97 If the latter is true, it would be in contrast to what
is known so far about the behaviour of MT2, considering that
its role is more close to Zn homeostasis, in contrast to MT1
which plays a more important role in Cd detoxification.39
Despite the up-regulation of theMT2 gene compared toMT1,
Adebambo et al. demonstrated in placental JEG-3 cells, that
when Cd exposure occurs together with arsenic (iAs), the general
expression of MTs and in particular of the MT1A, MT1F and
MT1G sub-isoforms is larger than in the presence of Cd alone.98
Since MT expression depends on the induction of the metal
regulatory transcription factor (MTF1), which once activated
binds the metal response elements (MRE),99,100 it is suggested
that the induction of MTF1 by the synergy between Cd and iAs
allows expression of more MTs than Cd by itself.98 Since the
induction of MTF1 is given by stimulation of one or more
kinases, one may hypothesize that the number of stimulated
kinases is larger in the presence of Cd and iAs, than in the case
of Cd alone.99
As a consequence of the upregulation of MTs by the presence
of Cd, they will form not only Cd–MT complexes, but also more
Zn–MT than in physiological conditions (Fig. 1). This will
decrease the availability of Zn in the placenta to be transferred
to the embryo/fetus, therefore explaining in part, the low con-
centrations of Zn in the cord blood, which contributes to low
fetal weight, as a result of the deficiency of this element.101,102
By contrast, although the synthesis of MT3 is not Cd-dependent,
it is significantly expressed in the uterus, even though the ratio of
MT3 concentrations to those of MT1 and MT2, suggests that
MT3 does not play a significant role in Cd detoxification in this
tissue72 (Table 1).
4.2. Maternal and cord blood
Several studies conducted in humans, analysed the maternal
and the cord blood of pregnant women exposed to Cd. They
showed that MT levels in the maternal plasma increase on Cd
exposure. However, there exist significant differences between
pregnant women depending on their MT2-5A/G single nucleotide
polymorphism. Thus, those mothers presenting the MT2-hetero-
zygote genotype have higher Cd concentration in maternal blood,
while the levels are lower in those with MT2-homozygosis.103,104
Concerning the cord blood of pregnant smokers, whose Cd
levels are higher than those of non-smokers, the concentration
in the cord blood is positively correlated with the increase in
cord jelly, whereas it is negatively associated with the arterial
and the umbilical cord diameters (Table 1). On the other hand,
it has also been demonstrated that in pregnancies diagnosed
with FGR, the MT levels in the cord blood are higher than in
those diagnosed with normal fetal growth.105 Likewise, a negative
relation between the Cd levels of heterozygote MT2 gene and the
Zn levels in cord blood103 has been established.
Meanwhile, comparing what happens in a non Cd-exposure
pregnancy where MTs in the cord blood are low, regarding the
Cd-exposure, no significant data are available to establish a
clear association between Cd-exposure and the increase or
decrease of MT concentrations in the cord blood, which could
indicate a possible dysregulation of MT function at this level.106
4.3. Fetus
The role of MT1 andMT2 in the fetus remains unclear. However, it
is known that overexpression of these MTs, and more precisely
MT2, in the placenta, protects against FGR induced by Cd.70 At the
same time, the placental MT synthesis allows the formation of
Cd–MT complexes, thus reducing Cd transport to the fetus.59,72
Despite the low levels of Cd detected in the fetus, MT
concentrations in the fetal liver are important.104 Likewise, it
has also been established that there is a comparable expression
of fetal MTs in the liver relative to those in the kidneys, because
of the similarity in the Cd concentrations found in both
organs.107 Moreover, the analogy of the pattern of MT synthesis
Fig. 1 Zinc (Zn) transport from the placenta to the cord blood, in the absence
(A) or presence (B) of cadmium (Cd). (A) Zn is imported to the placenta thanks
to ZIP14. Once inside the placenta, Zn can be bound to metallothioneins (MTs)
or transported to the fetus by means of metal-transporters (ZnT2 and DMT1).
(B) The presence of Cd upregulates the synthesis of the MT genes, which
implies an increase in the formation of Zn–MT and Cd–MT complexes in the
placenta. At the same time, the transport of Zn to the fetus decreases, due to its
low availability and this also decreases the number of Zn transporters. The Cd
transport at low doses to the fetus is mediated by DMT1.
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between the fetus and adult mammals, suggests the same
distribution of Cd in the organism.108 Compiling all this
information seems to indicate that although Cd reaches the
fetus at low concentrations, fetal MTs behave in a comparable
manner to those of the adult, thus contributing to the binding
of Cd by MTs and as a consequence, would reduce the toxicity
of the metal during the development and growth process to the
maximum.
4.4. Lactation (mammary glands and breast milk) and
newborns
Studies performed in rats showed that during the lactation
period, the synthesis of MTs increases in the kidneys, liver and
duodenum of the breastfeeding mother, and decreases a few days
after weaning.109 This rise in MT concentration is described as a
physiological process, since it does not depend on the presence of
toxic heavy metals. This determines the relevant role of MTs in
binding heavy metals, including low levels of Cd from dietary
intake on the mother’s side.110 Furthermore, formation of
Cd–MT complexes has also been established in the mammary
glands. Evenly, comparing non-smokers with smokers, lower
levels of MTs in the breast milk of smoking mothers have been
detected. This would seem to be beneficial to the newborn, since
the Cd–MT complex has proven to be toxic.111,112
In addition, studies conducted in rats by Mimouna et al.,
revealed an association between the presence of Cd in the
newborn brain during lactation, a significant increase of MT
synthesis in this tissue and its negative correlation with the
brain development113,114 (Table 1). In addition, it has also been
demonstrated that increased MT levels in the liver of lactating
dams corroborate the possible role of MTs retaining Cd to avoid
toxicity.44
According to this, and knowing that Cd–MT complexes
cause toxicity in kidneys,44 future studies should determine
the role of free Cd ions, as well as Cd–MT complexes in the
brain, and also in the central nervous system, kidneys, liver and
bones of the breastfed infant.
5. Conclusions
The exponentially rising presence of Cd is a threat for the
general population, and in the case of pregnancy and lactation
it poses a greater risk not only for the mother but also for the
fetus and the newborn. Cd can induce and regulate the synthesis
of a set of proteins in the tissues or organs where it is present
among which are included transporters like ZnT, ZIP and DMT1
proteins, as well as metal-binding proteins like MTs. Similarly,
the synthesis of MT genes in the placenta is induced as a
consequence of exposure to Cd, which plays an important role
in avoiding the transfer of the toxic metal to the fetus. However,
the formation of Cd–MT complexes does not completely prevent
this transfer, because some Cd(II) ions can cross the placenta with
the help of the DMT1 divalent metal transporter. As an indirect
effect, the high concentrations of MTs facilitate the binding of
Zn, reducing the availability of this metal to be transferred
through the placenta and cord blood. In conclusion, the Cd
exposure during pregnancy results in a combination of factors,
which will cause changes in the Zn availability that will eventually
affect the mother and the embryo/fetus or the newborn to a
greater or lesser extent.
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